How the Mark Foundation Is Rebuilding the Cancer R&D Model

Description

“I like the label ‘new operating system.’ I think that does capture well what we’re trying to do here,” says Dr. Ryan Schoenfeld, CEO of the Mark Foundation. In this episode of Vanguards of Health Care, Schoenfeld joins Bloomberg Intelligence analyst Sam Fazeli to explore how the foundation is redesigning cancer research through global collaboration, platform thinking and a bold portfolio approach. They discuss the Foundation’s growing international footpr int, why basic research is increasingly under threat in the US, and where new breakthroughs — including solid tumor CAR-T and glioblastoma — may emerge in the next five years.